Andy Jones
Contributor since: 2020
Articles
ADMA Biologics' 2021 Numbers Showed Continued Strong Execution
Tue, Mar. 29 ADMA15 Comments
Xeris Continues To Execute And Build Long-Term Value Potential
Tue, Feb. 22 XERS5 Comments
A Look At Recent Moves By Antares Pharma
Mon, Jan. 24 HALO12 Comments
Fennec Could See Upside If Pedmark Gets Approved
Jul. 29, 2021 FENC, FRX:CA7 Comments
A Look At Unity's UBX1325 Phase 1 Results
Jul. 26, 2021 UBX7 Comments
OptiNose: Growing Sales Make The Current Market Cap Look Very Low
Jul. 18, 2021 OPTN16 Comments
Harmony Biosciences Is Likely To Trade Higher As Wakix Sales Build
Jul. 13, 2021 HRMY4 Comments
The Xeris-Strongbridge Merger Should Create Substantial Value For Shareholders
Jun. 29, 2021 XERS26 Comments
Zogenix's Current Price Seems Disconnected From A Strong Fintepla Launch
Jun. 23, 2021 ZGNX10 Comments
Updated OpRegen Data Looks Promising For Lineage
Jun. 11, 2021 LCTX21 Comments
An Updated Look At Glaukos
Jun. 6, 2021 GKOS
Ocuphire's Low Market Cap Masks Significant Pipeline Potential
May 13, 2021 OCUP7 Comments
Sesen Bio: Long-Term And Short-Term Potential In Advance Of Its First PDUFA
May 7, 2021 SESN50 Comments
Paratek Offers Long-Term Value Potential In The Difficult Antibiotic Business
Apr. 27, 2021 PRTK30 Comments
Frequency Therapeutics: A Look At What's Next After A Disappointing Data Readout
Apr. 20, 2021 FREQ10 Comments
Phathom Pharmaceuticals Could See Substantial Upside With 2 Upcoming Phase 3 Readouts
Apr. 7, 2021 PHAT9 Comments
Aurinia Should Be A Long-Term Winner With Lupkynis Now On The Market
Mar. 24, 2021 AUPH53 Comments
Strong Reproxalap Results Give Aldeyra A Good Balance Of Risk Versus Potential Reward
Mar. 16, 2021 ALDX9 Comments
Yumanity: Speculative Upside Potential In Advance Of Multiple Near-Term Catalysts
Mar. 10, 2021 YMTX2 Comments
Jelmyto And UGN-102 Will Likely Drive Strong Returns For UroGen Shareholders
Mar. 1, 2021 URGN14 Comments
Dicerna Is A Reasonably Priced Play In The Attractive RNAi Space
Feb. 17, 2021 NVO13 Comments
PAVmed's Esophageal Diagnostic Tools Should Create Strong Shareholder Value
Feb. 9, 2021 PAVM36 Comments
Marketplace Contributors 2021 Top Ideas - Part 2
Feb. 2, 2021 ABUS, AMT, AVHHL31 Comments
Rigel Still Looks Modestly Undervalued Despite The Recent Rally
Jan. 25, 2021 RIGL24 Comments
G1 Therapeutics Likely Still Has Long-Term Upside Ahead Of The Trilaciclib PDUFA Date
Jan. 18, 2021 GTHX45 Comments
2021 Roundtable: General Outlook - Biotech And Healthcare Investing
Jan. 11, 2021 ETNB, KPTI, MRTX3 Comments
Provention Bio Could See Meaningful Upside Once Teplizumab Hits The Market
Jan. 7, 2021 PRVB23 Comments
BioXcel Therapeutics Has Compelling Upside Potential In Advance Of Multiple Data Readouts
Dec. 27, 2020 BTAI10 Comments
Kala Pharmaceuticals Should Have Limited Downside With Eysuvis Now Approved
Dec. 22, 2020 KALA16 Comments
Beyond Air Offers Compelling Value Heading Into Its First Potential Product Approval
Dec. 19, 2020 XAIR12 Comments
Chiasma Trades At A Big Discount To Fair Value With Mycapssa On The Market
Dec. 7, 2020 CHMA16 Comments
Eiger Looks Like A Solid Long-Term Play After Zokinvy's Approval
Nov. 30, 2020 EIGR15 Comments
A Look Inside Unity Biotechnology's Transition To An Ophthalmology Company
Nov. 27, 2020 UBX10 Comments
Savara's IMPALA 2 Trial Seems Well-Tailored To Get Positive Phase 3 Data For Molgradex
Nov. 23, 2020 SVRA7 Comments
Karyopharm Is Extremely Cheap After Recent Sell-Off
Nov. 16, 2020 KPTI43 Comments
Zogenix Has A Wide Margin Of Safety After A 60% Sell-Off
Nov. 12, 2020 ZGNX2 Comments
Frequency Therapeutics Is An Interesting Speculative Play Ahead Of Phase 2 Results
Nov. 9, 2020 FREQ14 Comments
The Sell-Off In Myovant Is Unjustified By Fundamentals
Nov. 9, 2020 MYOV13 Comments
Ardelyx Is An Even Bigger Value After Recent Sell-Off
Oct. 26, 2020 ARDX4 Comments
Evofem's Major Sell-Off Undervalues The Company's Long-Term Potential
Oct. 21, 2020 EVFM17 Comments